MOED方案治疗复发性或难治性恶性淋巴瘤38例临床观察  

Clinical analysis of MOED regiment for refractory and relapsing malignant lymphoma

作　　者：张红宾[1] 刘林[1] 肖青[1] 王建渝[1] 陈建斌[1] 胡妮妮[1] 黄宗干[1] 

机构地区：[1]重庆医科大学附属第一医院血液科,400016

出　　处：《重庆医学》2010年第11期1355-1356,共2页Chongqing medicine

摘　　要：目的探讨MOED(米托蒽醌、长春地辛、依托泊苷、地塞米松)方案治疗恶性淋巴瘤的疗效和安全性。方法采用MOED方案治疗38例难治性或复发性恶性淋巴瘤,其中难治性非霍奇金淋巴瘤(NHL)15例,复发性NHL 13例,难治性霍奇金淋巴瘤(HL)3例,复发性HL 7例。结果完全缓解(CR)14例(36.8%),部分缓解(PR)18例(47.4%);总有效率为84.2%。不良反应主要表现为不同程度的骨髓抑制以及消化道症状。结论 MOED方案治疗复发性或难治性恶性淋巴瘤疗效显著,且耐受性较好。Objective To investigate the safety and efficiency of MOED regiment in treatment for refractory and relapsing lymphoma.Methods 38 patients with refractory or relapsing malignant lymphoma（15 refractory NHL patients,13 relapsing NHL patients,3 refractory HL patients,7 relapsing patients）were treated with MOED regimen.Results The rate of complete remission was 36.8%（14/38）,the rate of partial remission was 47.4 %（18/38）,and the overall response rate was 84.2%.Main toxicities were gastrointestina1 side effects,mye1osuppression and neutropenia.Conclusion MOED regiment is effective and well tolerated in patients with relapsed or refractory NHL.

关 键 词：化疗 难治 淋巴瘤 

分 类 号：R733.1[医药卫生—肿瘤] R730.53[医药卫生—临床医学]